542.20% to Target, H.C. Wainwright Maintains “Buy” Rating for Viking Therapeutics (VKTX) Stock; Pacific Continental (PCBK) Sentiment Is 1.23

July 17, 2017 - By Richard Conner

Among 3 analysts covering Viking Therapeutics (NASDAQ:VKTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viking Therapeutics has $10 highest and $500 lowest target. $7’s average target is 542.20% above currents $1.09 stock price. Viking Therapeutics had 5 analyst reports since April 7, 2016 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Thursday, April 7 with “Buy”. As per Tuesday, May 24, the company rating was initiated by Maxim Group. The rating was maintained by Laidlaw with “Buy” on Thursday, August 11. The company was maintained on Wednesday, July 12 by Maxim Group. On Tuesday, June 6 the stock rating was maintained by Maxim Group with “Buy”.

Pacific Continental Corporation is a bank holding company. The company has market cap of $566.76 million. The Company’s principal business activities are conducted through its subsidiary, Pacific Continental Bank , an Oregon state-chartered bank with deposits insured by the Federal Deposit Insurance Corporation. It has a 26.61 P/E ratio. The Bank operates in three primary markets: Eugene, Oregon, Portland; Oregon/Southwest Washington, and Seattle, Washington.

It closed at $25.3 lastly. It is down 47.15% since July 17, 2016 and is uptrending. It has outperformed by 30.45% the S&P500.

Pacific Ridge Capital Partners Llc holds 1.63% of its portfolio in Pacific Continental Corporation for 207,423 shares. Signia Capital Management Llc owns 46,268 shares or 1.47% of their US portfolio. Moreover, Banc Funds Co Llc has 1.36% invested in the company for 1.47 million shares. The Texas-based Hillcrest Asset Management Llc has invested 1.34% in the stock. Alphaone Investment Services Llc, a Pennsylvania-based fund reported 214,292 shares.

Analysts await Pacific Continental Corporation (NASDAQ:PCBK) to report earnings on July, 19. They expect $0.33 EPS, up 22.22% or $0.06 from last year’s $0.27 per share. PCBK’s profit will be $7.39 million for 19.17 P/E if the $0.33 EPS becomes a reality. After $0.29 actual EPS reported by Pacific Continental Corporation for the previous quarter, Wall Street now forecasts 13.79% EPS growth.

It closed at $1.09 lastly. It is down 5.04% since July 17, 2016 and is uptrending. It has underperformed by 11.66% the S&P500.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $30.17 million. The Firm focuses on the development of therapies for metabolic and endocrine disorders. It currently has negative earnings. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: